The FDA Just Raised the Bar on Cybersecurity- we can help you clear it.
Cybersecurity is no longer a “nice to have.” It’s now a required element of safety and effectiveness throughout your device’s lifecycle.
On February 3, 2026, the FDA reissued its cybersecurity guidance to fully align with the new Quality Management System Regulation (QMSR) replacing the long‑standing QSR and formally embedding ISO 13485:2016 into how medical devices are evaluated.
If your device contains software — any software — this guidance affects you.
The FDA now expects manufacturers to show cybersecurity assurance through their:
If your quality system was compliant last year under the QSR, that doesn’t guarantee you’re compliant today under the QMSR. In addition to that, the FDA’s broadened definition of a “cyber device” now includes anything with potential connectivity:
— pulling far more devices under scrutiny. The updated guidance also reinforces expectations like SPDF, threat modeling, clear security architecture, machine‑readable SBOMs, and proof your device can be patched and maintained securely post-market.
What’s Actually Going On With the FDA’s 2026 Cybersecurity Update?
We help teams navigate this shift without slowing development.
When you work with us, Vantage can generate a vulnerability report, SBOM, and supply‑chain risk analysis, fast.
Vantage translates the new FDA expectations into clear, actionable steps.
We analyze your code base, expose vulnerabilities, generate SBOMs, identify supply‑chain risks, and help you modernize legacy components before they become regulatory blockers.